Teva jumps on Ajovy’s impact in children

5 December 2024

Shares in Teva Pharmaceutical Industries (NYSE: TEVA) closed more than 5% higher on Wednesday.

The Israeli drugmaker earlier presented positive data from its Phase III SPACE study evaluating the efficacy and safety of Ajovy (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged six to 17 years.

Ajovy, a calcitonin gene-related peptide (CGRP) receptor antagonist, showed statistically significant superior efficacy compared to placebo over 12 weeks with a favourable safety profile consistent with that observed in the adult population.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK